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Abstract
Background: Lyme borreliosis (LB) is a tick-borne disease caused by spirochetes belonging to the Borrelia burgdorferi
sensu lato species. Due to a variety of clinical manifestations, diagnosing LB can be challenging, and laboratory work-
up is usually required in case of disseminated LB. However, the current standard of diagnostics is serology, which
comes with several shortcomings. Antibody formation may be absent in the early phase of the disease, and once IgG-
seroconversion has occurred, it can be difficult to distinguish between a past (cured or self-cleared) LB and an active
infection. It has been postulated that novel cellular tests for LB may have both higher sensitivity earlier in the course of
the disease, and may be able to discriminate between a past and active infection.
Methods: VICTORY is a prospective two-gate case-control study. We strive to include 150 patients who meet the
European case definitions for either localized or disseminated LB. In addition, we aim to include 225 healthy controls
without current LB and 60 controls with potentially cross-reactive conditions. We will perform four different cellular
tests in all of these participants, which will allow us to determine sensitivity and specificity. In LB patients, we will
repeat cellular tests at 6 weeks and 12 weeks after start of antibiotic treatment to assess the usefulness as ‘test-of-cure’.
Furthermore, we will investigate the performance of the different cellular tests in a cohort of patients with persistent
symptoms attributed to LB.
Discussion: This article describes the background and design of the VICTORY study protocol. The findings of our study
will help to better appreciate the utility of cellular tests in the diagnosis of Lyme borreliosis.
Trial registration: NL7732 (Netherlands Trial Register, trialregister.nl).
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Background
Lyme borreliosis (LB) is a widely prevalent infectious
disease in the Northern Hemisphere with potentially
major health consequences [1, 2]. The causative agent of
LB is one of several species of bacteria from the Borrelia
burgdorferi sensu lato complex, which require the tick as
a vector for transmission. LB can be arbitrarily divided
into early localized, early disseminated and late (dissemi-
nated) manifestations [3]. Common manifestations in
Europe include erythema migrans (EM), Lyme neurobor-
reliosis (LNB), Lyme arthritis and acrodermatitis chron-
ica atrophicans (ACA) [4, 5].
The diagnosis of LB is primarily based on clinical
features, usually combined with serological testing or,
when indicated, direct detection of the pathogen in spe-
cific bodily materials. As holds true for many serological
tests for infectious diseases, Borrelia serology comes
with several shortcomings. Sensitivity and specificity
depend on several factors, which include the disease
duration and type of manifestation. Moreover, an inher-
ent issue with serological testing is the fact that antibody
formation takes time and can be aborted after antibiotic
treatment [6, 7]. A recent review by Leeflang and
colleagues found the overall sensitivity of ELISAs and
immunoblots used in Europe to be up to 95% for late
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manifestations, but as low as 50% for early localized
disease (EM) [8]. Specificity ranged from 80 to 95% [8].
An additional problem arises once IgG-seroconversion
has occurred, since antibodies oftentimes remain present
in the blood for many years, even after the infection has
long been cured or self-cleared [7, 9, 10]. These test
characteristics result in diagnostic dilemmas in several
clinical situations for both patients and physicians.
Some LB patients report persistent symptoms, with
the exact percentage varying per manifestation and
population assessed [11–14]. These complaints cause a
substantial disease burden in the Netherlands [15].
These symptoms may develop after early, disseminated
or late manifestations of LB, despite recommended
antibiotic treatment. These symptoms, which mainly
include fatigue, general malaise, musculoskeletal pain
and neurological symptoms, are more likely to occur
when there has been a delay in proper antibiotic treat-
ment [16, 17]. For this reason, an early diagnosis of LB
has clear treatment benefits. Antibiotic treatment failure,
defined as microbiologically confirmed persisting B.
burgdorferi s.l. infection, is uncommon, but has been
described [18]. Therefore, a discussion may ensue about
whether complaints are caused by a persisting infection
(requiring antibiotic treatment), if these symptoms are
post-infectious or not even related to LB. Serology
cannot make this distinction once seroconversion has
occurred.
Cellular tests for LB have been proposed as a (par-
tial) solution to some of these dilemmas. These tests
utilize the cellular part of the immune system and
have been in use for the diagnosis of tuberculosis
for several decades [19]. These in vitro assays func-
tion by stimulating patient leukocytes with pathogen-
specific antigens and measuring the resulting cellular
response. Previous studies have examined the diag-
nostic value of various types of cellular tests for LB
and have yielded varying results [20–32]. A more re-
cent study by Callister and colleagues found that the
sensitivity of a cellular assay for LB based on inter-
feron-gamma (IFN-γ) was higher than that of ser-
ology in patients with early localized LB (an EM). In
addition, the authors showed that the IFN-γ re-
sponse waned within months after antibiotic treat-
ment [33]. This supports the hypothesis that cellular
tests may have a higher sensitivity than serology
earlier in the course of disease, and that they may
be used a test-of-cure (i.e. positive before treatment
and negative after successful treatment). For patients
who have long-lasting –sometimes invalidating–
complaints that are attributed to LB, a test that bet-
ter distinguishes between a persistent Borrelia-infec-
tion, post-treatment Lyme borreliosis syndrome
(PTLBS) or an altogether different condition could
be of great benefit, and could thus guide patient
management.
The aforementioned studies investigating cellular tests
for LB had important shortcomings. They lacked clear
case definitions, were performed in only a small number
of participants, or they lacked comparisons with
adequate control groups. In addition, many of these
studies were performed by the developers of the tests,
with insufficient safeguards to prevent a potential
conflict of interest. Conversely, the present VICTORY
study has been designed to assess the diagnostic per-
formance of various cellular tests for LB in well-defined
groups of patients with acute LB and controls by means
of a two-gate case-control design. Additionally, we will
study the utility of these tests in an observational cohort
of patients with prolonged symptoms attributed to LB.
In this paper, we describe the study protocol in detail.
Methods/design
Study design
This is a multi-center prospective two-gate case-control
study with 1 year of follow-up to assess the diagnostic
parameters of cellular tests for LB. In addition, an obser-
vational prospective cohort is included to investigate the
performance of cellular tests in patients with persistent
symptoms attributed to LB. This study entails a collabor-
ation between the Dutch National Institute for Public
Health and the Environment (RIVM, Bilthoven, the
Netherlands) and the clinical expert centers for Lyme
borreliosis at the Amsterdam UMC (formerly AMC,
Amsterdam, the Netherlands), and the Radboud univer-
sity medical center (Radboudumc, Nijmegen, the
Netherlands). The study has been approved by the
medical ethics committee (MEC) of the Amsterdam
UMC (registered under no. NL63961.018.18), and is
conducted according to the principles of the Declaration
of Helsinki.
Study population
We will enroll three groups in the case-control study.
Cases are 150 adults from the Netherlands with acute
confirmed LB, included before or just after start of
antibiotic treatment (Table 1). Our study uses well-
established case definitions that largely match the
European case definitions as described by Stanek and
colleagues [3]. LB patients have early localized, early
disseminated, or late disseminated LB. We are also
recruiting 225 participants from the general population,
who have no current complaints of LB. These partici-
pants function as healthy controls in the validation
study. Healthy controls are matched with cases by age,
gender, and – in order to correct for tick bites – by
geographical region. We are enrolling a separate control
cohort of 60 participants with medical conditions that
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are potentially cross-reactive with LB in these cellular
tests. These medical conditions include other spirochetal
infections (leptospirosis, syphilis), infection with Epstein-
Barr virus (EBV) or cytomegalovirus (CMV), and
rheumatoid arthritis (RA). Furthermore, the cellular tests
are performed in an observational cohort of participants
with persistent symptoms attributed to LB. All adult par-
ticipants visiting the Lyme outpatient clinics of the
Amsterdam UMC or Radboudumc are eligible for the
observational cohort and participants are included con-
secutively. Recruitment has started in May 2018.
Recruitment, inclusion and follow-up of participants
The majority of LB cases are recruited as part of the
LymeProspect study, which is also a collaborative ef-
fort of the RIVM, Amsterdam UMC and Radboudumc
(Netherlands Trial Register: NTR4998/NL4744) [34].
Cases with disseminated LB are additionally recruited
under the current protocol. The recruitment proce-
dures, and in- and exclusion criteria for cases are
identical in both protocols.
Table 1 Inclusion and exclusion criteria
Patients with confirmed Lyme borreliosis
Inclusion criteria:
Patient ≥18 years with confirmed proven or probable, early localized
or disseminated Lyme borreliosis manifestation.a
In case of an EM reported at www.tekenradar.nl, the EM has been
present < 3 months and the clinical diagnosis has been confirmed by
the general practitioner.
Subjects live or stay on the mainland of the Netherlands.
Exclusion criteria:
Subjects unable to provide informed consent or do not have
sufficient proficiency in the Dutch language.
Subjects having started antibiotic treatment > 4 days before inclusion
(for subjects included online) or > 7 days before inclusion (for subjects
included through the clinical expert centers).
Subjects having ongoing signs or symptoms attributed to a previous
episode of Lyme borreliosis.
Healthy controls
Inclusion criterium:
Participant ≥18 years old.
Exclusion criteria:
Uncontrolled HIV-infection, if known. This is defined as an HIV-1 viral
load > 40 copies/ml and/or CD4+ count < 500 × 106 cells/liter in the
past 12 months.
Active syphilis or leptospirosis, an active infection with EBV/CMV, or
an auto-immune disease, if known.
Current LB with typical symptoms. A past episode or Borrelia
seropositivity is not an exclusion criterium.
Immunomodulating medication including > 7.5 mg prednisone daily,
methotrexate, biologicals. Medication such as hydroxychloroquine,
sulfazalazine or NSAIDs are accepted.
Known immunodeficiency, hematologic malignancies in the medical
history or chemotherapy during the past year.
Subjects unable to provide informed consent or do not have
sufficient proficiency in the Dutch language.
Potentially cross-reactive controls
Inclusion criteria:
Participant ≥18 years old.
AND
1. Patients with syphilis:
EITHER clinical symptoms suspected of secondary syphilis, in
combination with a positive RPR card POCT result.
OR early latent syphilis infection with VDRL/RPR ≥ 1:32.
2. Patients with Epstein Barr-virus or cytomegalovirus:
Compatible signs and symptoms.
Positive IgM or Paul-Bunnell of EBV/CMV on plasma.
3. Patients with leptospirosis:
Compatible signs and symptoms.
Positive serology (MAT), preferably confirmed by culture or PCR.
Table 1 Inclusion and exclusion criteria (Continued)
4. Patients with autoimmune diseases:
EITHER confirmed rheumatoid arthritis.
OR other autoimmune disorders diagnosed according to the leading
guidelines.
Exclusion criteria:
Uncontrolled HIV-infection, if known. This is defined as an HIV-1 viral
load > 40 copies/ml and/or CD4+ count < 500 × 106 cells/liter in the
past 12 months.
More than one of the listed potentially cross-reactive conditions, if
known.
Ever an episode of LB, ever treated for LB or a known tick bite in the
past 6 months.
Immunomodulating medication including > 7.5 mg prednisone daily,
methotrexate, biologicals. Medication such as hydroxychloroquine,
sulfazalazine or NSAIDs are accepted.
Known immunodeficiency, hematologic malignancies in the medical
history or chemotherapy during the past year.
Subjects unable to provide informed consent or do not have
sufficient proficiency in the Dutch language.
Observational cohort
Inclusion criteria:
Participants ≥18 years old.
Presenting at the specialized Lyme centers of the Amsterdam UMC or
Radboudumc.
Exclusion criterium:
Subjects unable to give informed consent or do not have sufficient
proficiency in the Dutch language.
a Specific criteria for each manifestation of confirmed Lyme borreliosis are
identical to the criteria listed in the LymeProspect study protocol [34].
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Recruitment, inclusion and follow-up of LB cases
occur both online and at the LB clinical expert centers
(Fig. 1). Most LB cases are recruited through the website
Tekenradar.nl. This national and secured online enroll-
ment platform is operated by the RIVM. Patients can
visit the website on their own initiative, or after having
been referred to it by their general practitioner (GP). Pa-
tients thus recruited primarily have an EM as manifest-
ation of LB, but other forms of confirmed LB may be
included through Tekenradar.nl as well. Written
informed consent is obtained from eligible participants.
Importantly, the participant’s medical doctor is
consulted to verify the diagnosis after online enrollment.
Blood collection can be done locally or in the participat-
ing hospitals and is performed at baseline, after 6 weeks
and facultatively after 12 weeks. A secondary inclusion
route for cases is through the LB clinical expert centers,
after evaluation by one of the investigators (Table 2).
Controls are only recruited under the current protocol.
Healthy controls are recruited in two ways. Firstly, from
the general population, i.e. from a cohort that has previ-
ously been recruited to fill out questionnaires as a popu-
lation control for other LB-related studies. Additionally,
we recruit healthy controls through local laboratories,
GP’s offices and outpatient clinics. After obtaining
written informed consent, blood is drawn only at base-
line (Table 3). Next to inclusion through the Amsterdam
UMC or Radboudumc, potentially cross-reactive con-
trols are recruited through various medical institutions.
Persons with syphilis may also be recruited through the
sexually transmitted infections (STI) clinic of the
Amsterdam Public Health Service. Persons with an
autoimmune disease may be recruited from the Sint
Maartenskliniek for rheumatology in Nijmegen. Persons
with leptospirosis and an infection with EBV/CMV are
only recruited from the Amsterdam UMC or Radbou-
dumc. After obtaining written informed consent, blood
is drawn only at baseline (Table 3).
Participants for the observational cohort with persist-
ent symptoms attributed to LB are recruited from the
LB clinical expert centers of the Amsterdam UMC or
Radboudumc. After obtaining written informed consent,
blood is drawn at baseline and after 12 weeks (Table 4).
Epidemiological and clinical measurements
For LB cases and for participants in the observational
cohort, standard demographical characteristics, co-
morbidities and details on previous tick exposure and
Fig. 1 Flowchart of study design
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previous or current episodes of LB are reported at
baseline. During follow-up, new tick bites or new epi-
sodes of LB are recorded, as well as new non-LB-re-
lated medical diagnoses. Photographs of skin
manifestations of LB are obtained for blinded evalu-
ation by independent experts. Participants who are in-
cluded online can upload these pictures themselves.
Cases with confirmed LB who have a skin manifest-
ation have the option of giving additional informed
consent for skin biopsies to be taken (Table 2). For
all controls, standard demographical characteristics,
comorbidities and details on any previous episodes of
LB are recorded only at baseline (Table 3).
Laboratory measurements
Four cellular tests for LB will be performed: the Spirofind
Revised (Oxford Immunotec), the QuantiFERON-LB (QIA-
GEN Sciences), the Lyme iSpot (Autoimmun Diagnostika /
Genome Identication Diagnostics), and the Lymphocyte
Transformation Test-Memory Lymphocyte Immunostimu-
lation Assay (LTT-MELISA, InVitaLab). Details of the vari-
ous cellular tests are provided in the Additional file 1. The
B. burgdorferi s.l. C6 ELISA (Oxford Immunotec) is per-
formed as serological test. All positive and indeterminate
C6 ELISA results will be confirmed by IgM and IgG immu-
noblot (Mikrogen), according to guideline recommenda-
tions [35]. All samples are processed blinded, i.e. without
any markings related to the identity of the participant, type
of participant or time point.
Table 3 Data collection and measurements for healthy controls
and potentially cross-reactive controls
Baseline 3 months
Written information and informed consent X
Baseline characteristics X
Recording adverse events X X
Laboratory measurements
B. burgdorferi s.l. serology X
Spirofind Revised X
QuantiFERON-LB X
iSpot Lyme X
LTT-MELISA X
For explanation of abbreviations, see the main text
Table 2 Data collection and measurements for Lyme borreliosis cases
Baseline 10
days
2
weeks
6
weeks
3
months
6
months
9
months
12
months
Written information and informed consent X
Baseline characteristics X
Physical examination Xa Xac Xac Xac Xac
Recording LB manifestation, treatment and concomitant medication X Xb X X X X
Recording adverse events X Xb X X Xa
Laboratory measurements
B. burgdorferi s.l. serology X Xac X Xac
Spirofind Revised X X Xc
QuantiFERON-LB X X Xc
iSpot Lyme X X Xc
LTT-MELISA X X Xc
Biopsies from skin manifestations (optional) Xcd Xcd Xcd
Questionnaires
CIS1 (subscale fatigue), SF-36 (subscale pain), CFQ X Xe X Xe X
Clinical parameters: PHQ-15, SF-36 (subscale physical functioning and
subscale social functioning), TiC-P (health care use and absenteeism of work)
X X X X X
Cognitive-behavioral parameters: brief IPQ, CBRSQ, HADS, SES-F, PCS, IPAQ X X X
Comorbidities: TiC-P (co-morbidity list) X X
Comorbidities: PREDIS X
For explanation of abbreviations, see the main text
aPatients included through the clinical expert centers for Lyme borreliosis only
bPatients included through the website www.tekenradar.nl only. cThese visits and laboratory measurements can be left out if patients are not able or not willing
to. This is regarded as an allowed deviation from the protocol
dThree skin biopsy samples of the skin lesion at baseline and if still present at 6 weeks or at 3 months time point. eCIS questionnaire only short version, to limit
the burden for patients
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Questionnaires
Confirmed LB cases and participants in the observa-
tional cohort will also be asked to fill out online
questionnaires through Tekenradar.nl. These will be
filled out at inclusion, and after 3, 6, 9 and 12 months
and cover a wide array of determinants of health, in-
cluding assessment of symptoms, disabilities, cogni-
tive-behavioral variables, co-morbid disorders and
pre-existing symptoms. These questionnaires are vali-
dated and have Dutch norm scores, which enables us
to use cutoff scores to determine the severity of
symptoms. These questionnaires are specified in the
Additional file 1.
Outcome measures and data analysis
The primary outcome measures are the diagnostic pa-
rameters of the cellular tests in cases versus healthy con-
trols. We will use the manufacturer-prescribed reference
values for interpretation (positive, indiscriminate, nega-
tive), and perform a receiver operating characteristic
(ROC-) analysis to assess potential new cutoffs. From
this, we will calculate the diagnostic parameters (sensi-
tivity and specificity) of the studied tests.
Secondary outcome measures are: i) the comparisons
of the diagnostic parameters of the various cellular tests,
ii) the correlation of cellular tests with serology results,
and iii) the effectiveness of the cellular tests as a test-of-
cure. The latter outcome is determined by correlating
the cellular responses in LB participants over time to
various determinants of health during the one-year fol-
low-up period. Finally, we will assess the performance of
the cellular tests and clinical outcomes in the observa-
tional cohort of patients with persistent symptoms
attributed to LB.
Sample size
We consider cellular tests to be an improvement over
serology if they increase the sensitivity of laboratory
testing for early LB by 20%, with specificity not dropping
below 90%. Inclusion of 100 cases would result in a
power of 97% (alpha < 0.05) to detect a significant
improvement in sensitivity of 20%. Accounting for loss-
to-follow-up, and the fact that the improvement in
sensitivity may actually be smaller, we have chosen to
include 150 cases in our case-control study. This would
still yield a power of 85% (alpha < 0.05) to detect an
improvement in sensitivity of 10–15%. We will addition-
ally include 225 healthy controls and 60 potentially
cross-reactive controls in the case-control study. For the
observational cohort of patients with persistent signs
and symptoms attributed to LB, we aim to include 150
participants. Details on the power calculations are
provided in the Additional file 1.
Table 4 Data collection and measurements for the observational cohort
Baseline 6
weeks
3
months
6
months
9
months
12
months
Written information and informed consent X
Baseline characteristics X
Physical examination X
Recording LB manifestation, treatment and concomitant medication X X X X X
Recording adverse events X X X X
Laboratory measurements
B. burgdorferi s.l. serology X X
Spirofind Revised X X
QuantiFERON-LB X X
iSpot Lyme X X
LTT-MELISA X X
Questionnaires
CIS1 (subscale fatigue), SF-36 (subscale pain), CFQ X Xa X Xa X
Clinical parameters: PHQ-15, SF-36 (subscale physical functioning and subscale social
functioning), TiC-P (health care use and absenteeism of work)
X X X X X
Cognitive-behavioral parameters: brief IPQ, CBRSQ, HADS, SES-F, PCS, IPAQ X X X
Comorbidities: TiC-P (co-morbidity list) X X
Comorbidities: PREDIS X
For explanation of abbreviations, see the main text
aCIS questionnaire only short version, to limit the burden for patients
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Discussion
The VICTORY study evaluates the diagnostic param-
eters of cellular tests for LB and additionally assesses
their performance in an observational cohort of pa-
tients with persistent symptoms attributed to LB.
Cellular tests for LB may possibly help in clinical
decision making for LB-related problems. National
and international guidelines dictate that an EM is a
clinical diagnosis and that serological tests should not
be performed, as the chance of a false-negative result
is considerable [3, 35]. However, the skin lesion is
frequently atypical, and in approximately 50% of the
cases there is no known history of a tick bite [36,
37], which makes the diagnosis considerably more dif-
ficult. Furthermore, the clinical spectrum of early LB
can be broad, especially in the United States, where
subfebrile temperature and other systemic symptoms
are more common in early LB [36, 38, 39]. In such
situations, a test with a higher sensitivity and specifi-
city early in disease may lead to an earlier diagnosis.
Several studies have reported on the potential of
cellular tests for LB. However, these studies have im-
portant shortcomings, which have also been discussed
by others [40–43]. Nonetheless, several cellular tests for
LB are commercially available in Europe. In the absence
of a thorough assessment of the diagnostic parameters
of these commercially available tests, clinicians cannot
reliably use the test results in their clinical decision
making process. The results of any such unvalidated
tests do, however, give the patient an expectation of
health or illness. This underscores the urgent need for a
proper validation study for cellular tests for LB.
Our study is unprecedented compared to other studies
on cellular tests for LB, as the patient populations and
diagnoses are strictly defined according to consensus
criteria, the study includes healthy controls from the
general population and potentially cross-reactive
controls, and is appropriately powered. Furthermore, a
variety of cellular tests will be compared in parallel.
Finally, this study has been designed and is currently be-
ing performed in direct collaboration with patient repre-
sentatives taking into account the patients’ perspective.
As there is no universally applicable reference standard
for LB, it is challenging to set up a sufficiently powered
one-gate cohort study to assess the diagnostic parame-
ters of the cellular tests under study [44]. However, in
our study, the strict case definitions and physician con-
firmation of diagnosis function as a surrogate for this
missing reference standard.
In conclusion, the VICTORY study is a hybrid study
consisting of a prospective two-gate case-control study to
assess the diagnostic parameters of multiple cellular tests
for LB, and an observational prospective cohort study to
assess their clinical application in an outpatient setting.
Additional file
Additional file 1: (1) Specifics of laboratory measurements. (2)
Questionnaires. (3) Sample size calculation. (PDF 378 kb)
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